派特灵联合重组人干扰素α2b栓治疗老年低度宫颈上皮内瘤变的临床研究

发布时间：2018-03-03 06:00

本文选题：派特灵　切入点：重组人干扰素αb栓　出处：《中国临床药理学杂志》2017年12期 　论文类型：期刊论文

【摘要】：目的观察派特灵联合重组人干扰素α2b栓治疗老年低度宫颈上皮内瘤变(CIN)的临床疗效及安全性。方法将48例老年低度CIN患者随机分为对照组24例和试验组24例。对照组予以重组人干扰素α2b栓1.0×105U,每2天1次,睡前置于阴道后穹隆;试验组在对照组治疗的基础上,加用派特灵0.5mL,qd,局部湿敷,1个月后改为每2天1次。2组患者均治疗3个月。比较2组患者的临床疗效、血清脂肪细胞因子Chemerin、白细胞介素-10(IL-10)、IL-18水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的有效率分别为83.34%(20/24例)和54.17%(13/24例),差异有统计学意义(P0.05)。治疗后,试验组和对照血清Chemeri分别为(939.47±104.43),(1204.54±115.34)ng·L~(-1);IL-10分别为(210.47±30.06),(262.45±29.77)pg·mL~(-1);IL-18分别为(181.23±22.34),(235.34±23.17)pg·mL~(-1),差异均有统计学意义(均P0.05)。试验组的药物不良反应为局部轻微疼痛,对照组的药物不良反应为一过性低热,2组患者的药物不良反应发生率均为4.17%,差异无统计学意义(P0.05)。结论派特灵联合重组人干扰素α2b栓治疗老年低度CIN的临床疗效显著,其能够显著降低患者的血清Chemerin、IL-10和IL-18水平,且不增加药物不良反应的发生率。
[Abstract]:Objective To observe Paiteling combined with recombinant human interferon alpha 2b suppository in the treatment of senile low-grade cervical intraepithelial neoplasia (CIN) clinical efficacy and safety. Methods 48 patients with low-grade CIN patients were randomly divided into control group of 24 cases and 24 cases in the experiment group. The control group received recombinant human interferon alpha 2b suppository 1 * 105U, 1 every 2 days, before going to bed in the posterior fornix of vagina; the experimental group based on the treatment in control group, with Trane 0.5mL, QD, local wet dressing, 1 months after the change for every 2 days of 1.2 patients were treated for 3 months. The clinical efficacy of the 2 groups of patients, serum adipocytokines in Chemerin and interleukin -10 (IL-10), the level of IL-18, and the occurrence of adverse drug reactions. Results after treatment, the test group and control group were 83.34% (20/24 cases) and 54.17% (13/24 cases), the difference was statistically significant (P0.05). After treatment, the test group and control serum (939. Chemeri respectively. 47 + 104.43), (1204.54 + 115.34) ng - L~ (-1); IL-10 = (210.47 + 30.06), (262.45 + 29.77) PG - mL~ (-1); IL-18 = (181.23 + 22.34), (235.34 + 23.17) PG - mL~ (-1), the differences were statistically significant (P0.05). Drug adverse reaction in the experimental group for slight pain, the control group of adverse drug reactions as a fever, adverse drug reactions of the 2 groups of patients the incidence rate was 4.17%, the difference was not statistically significant (P0.05). Conclusion the curative effect of Paiteling combined with recombinant human interferon alpha 2b suppository in the treatment of elderly low CIN obviously, it can significantly reduce the serum Chemerin, IL-10 and IL-18 levels, and does not increase the incidence of adverse drug reactions.

【作者单位】：瑞安市妇幼保健院妇科;
【基金】：浙江省医药卫生科技计划基金资助项目(2011ZDA015)
【分类号】：R737.33

【相似文献】